Literature DB >> 2029803

Pharmacokinetics of diflunisal in patients.

B Nuernberg1, G Koehler, K Brune.   

Abstract

There are few pharmacokinetic data available on the disposition of diflunisal in patients; this study, therefore, looked at the oral absorption, distribution and elimination of this drug. Ten pharmacokinetic profiles obtained from 8 patients showed a maximum plasma diflunisal concentration of 62.0 +/- 26.5 mg/L after 2.76 +/- 1.87 hours, and an area under the plasma concentration-time curve (AUC) of 678.3 +/- 362.3 mg/L.h. Significant intra- and intersubject variability was observed in this group of patients. Analysis of biliary secretion of diflunisal in 4 patients suggested a biliary elimination and subsequent enterohepatic circulation ranging between 2.4 and 15.1%. The AUC for diflunisal in synovial fluid collected from 66 patients was about 70% of that for plasma. In none of 28 patients studied could any trace of diflunisal be observed in cerebrospinal fluid, even though the sensitivity of the assay allowed detection of concentrations as low as 0.01 mg/L.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2029803     DOI: 10.2165/00003088-199120010-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  34 in total

1.  Stereoselective disposition of ibuprofen enantiomers in synovial fluid.

Authors:  R O Day; K M Williams; G G Graham; E J Lee; R D Knihinicki; G D Champion
Journal:  Clin Pharmacol Ther       Date:  1988-05       Impact factor: 6.875

2.  Diflunisal disposition. Role of gastric absorption in the development of mucosal damage and anti-inflammatory potency in rodents.

Authors:  B Nuernberg; I Szelenyi; H T Schneider; K Brune
Journal:  Drug Metab Dispos       Date:  1990 Nov-Dec       Impact factor: 3.922

Review 3.  Pathophysiologic factors affecting the pharmacokinetics of nonsteroidal antiinflammatory drugs.

Authors:  R K Verbeeck
Journal:  J Rheumatol Suppl       Date:  1988-10

Review 4.  Variability in response to NSAIDs. Fact or fiction?

Authors:  R O Day; G G Graham; K M Williams; P M Brooks
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

5.  The pharmacokinetics of etodolac in serum and synovial fluid of patients with arthritis.

Authors:  M Kraml; D R Hicks; M McKean; J Panagides; D Furst; J Furst
Journal:  Clin Pharmacol Ther       Date:  1988-05       Impact factor: 6.875

6.  Non-steroidal analgesic and anti-inflammatory agents.

Authors:  G Nuki
Journal:  Br Med J (Clin Res Ed)       Date:  1983-07-02

7.  Buffering the stomach content enhances the absorption of diflunisal in man.

Authors:  B Nuernberg; K Brune
Journal:  Biopharm Drug Dispos       Date:  1989 Jul-Aug       Impact factor: 1.627

8.  Total and free ketoprofen in serum and synovial fluid after intramuscular injection.

Authors:  P Netter; B Bannwarth; F Lapicque; J M Harrewyn; A Frydman; J N Tamisier; A Gaucher; R J Royer
Journal:  Clin Pharmacol Ther       Date:  1987-11       Impact factor: 6.875

9.  The diffusion of pirprofen into the cerebrospinal fluid in man.

Authors:  L Zecca; M Broggini; R Pirola; R Campi; P Ferrario; E Bichisao; V Maresca
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 10.  Review of the animal and clinical pharmacology of diflunisal.

Authors:  R O Davies
Journal:  Pharmacotherapy       Date:  1983 Mar-Apr       Impact factor: 4.705

View more
  5 in total

1.  Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth.

Authors:  Bo Ram Kim; Etienne Coyaud; Estelle M N Laurent; Jonathan St-Germain; Emily Van de Laar; Ming-Sound Tsao; Brian Raught; Nadeem Moghal
Journal:  Mol Cell Proteomics       Date:  2017-08-09       Impact factor: 5.911

Review 2.  The spinal actions of nonsteroidal anti-inflammatory drugs and the dissociation between their anti-inflammatory and analgesic effects.

Authors:  K McCormack
Journal:  Drugs       Date:  1994       Impact factor: 9.546

3.  Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity.

Authors:  Kotaro Shirakawa; Lan Wang; Na Man; Jasna Maksimoska; Alexander W Sorum; Hyung W Lim; Intelly S Lee; Tadahiro Shimazu; John C Newman; Sebastian Schröder; Melanie Ott; Ronen Marmorstein; Jordan Meier; Stephen Nimer; Eric Verdin
Journal:  Elife       Date:  2016-05-31       Impact factor: 8.140

Review 4.  Central mediators involved in the febrile response: effects of antipyretic drugs.

Authors:  Aleksander R Zampronio; Denis M Soares; Glória E P Souza
Journal:  Temperature (Austin)       Date:  2015-10-13

Review 5.  Organic solute carrier 22 (SLC22) family: Potential for interactions with food, herbal/dietary supplements, endogenous compounds, and drugs.

Authors:  Raymond E Lai; Christopher E Jay; Douglas H Sweet
Journal:  J Food Drug Anal       Date:  2018-03-24       Impact factor: 6.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.